E3-Hormone Refractory Prostrate Cancer Taxotere Combination
Status:
Completed
Trial end date:
2008-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether treatment with Zactima (vandetanib) in
combination with Docetaxel and Prednisolone is more effective than the standard Docetaxel and
Prednisolone alone for prostate cancer, in patients with Hormone refractory prostate cancer
who have not previously received chemotherapy.